JBIO Jade Biosciences, Inc.
Nasdaq · SEC CIK 1798749 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 184 since 2021-07-01, latest 2026-06-26 21:20
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Balta Elizabeth | See Remarks | — | — |
| Frohlich Tom | CEO, Dir | — | — |
| King Andrew James | See Remarks | — | — |
| Dahms Bradford D. | CFO | — | — |
| Fairmount Healthcare Fund II L.P. | Dir, 10% | — | — |
Transactions 208
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-07-06 | 2021-07-02 | JBIO | Atlas Venture Fund XII, L.P. | 10% | P - Purchase | $14.00 | +535.7K | 3.10M | +21% | +$7.50M |
| D | 2021-07-06 | 2021-07-02 | JBIO | Atlas Venture Fund XII, L.P. | 10% | C - Cnv Deriv | — | +2.57M | 2.57M | New | — |
| DI | 2021-07-06 | 2021-07-02 | JBIO | GRAYZEL DAVID S. | Dir | C - Cnv Deriv | — | +2.57M | 2.57M | New | — |
| DI | 2021-07-06 | 2021-07-02 | JBIO | GRAYZEL DAVID S. | Dir | P - Purchase | $14.00 | +535.7K | 3.10M | +21% | +$7.50M |
| DI | 2021-07-06 | 2021-07-02 | JBIO | Katabi Maha | Dir, 10% | C - Cnv Deriv | — | +3.40M | 3.40M | New | — |
| DI | 2021-07-06 | 2021-07-02 | JBIO | Katabi Maha | Dir, 10% | P - Purchase | $14.00 | +357.1K | 3.76M | +10% | +$5.00M |
| D | 2021-07-06 | 2021-07-02 | JBIO | Sofinnova Venture Partners X, L.P. | 10% | C - Cnv Deriv | — | +3.40M | 3.40M | New | — |
| D | 2021-07-06 | 2021-07-02 | JBIO | Sofinnova Venture Partners X, L.P. | 10% | P - Purchase | $14.00 | +357.1K | 3.76M | +10% | +$5.00M |
Purchase Sale Sale after option exercise All abbreviations